Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia

了解和针对急性髓系白血病的化疗耐药性

基本信息

  • 批准号:
    8946188
  • 负责人:
  • 金额:
    $ 67.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-07-22 至 2020-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Chemotherapy resistance is the most important clinical challenge in treating patients with acute myeloid leukemia (AML). The majority of patients with AML initially respond to chemotherapy but over half of responders will relapse and eventually die of disease. Traditionally, chemotherapy resistance is hypothesized to represent selection for a genetically distinct clone that has properties of leukemic stem cells (LSC). Recent data and our preliminary results (below) indicate that neither part of this model is fully correct. Rather, we propose that chemotherapy resistance can and frequently is an acquired epigenetic response to chemotherapeutic challenge that may arise in any leukemic clone. In vitro, we have modeled chemotherapy resistance and demonstrate that both DNA methylation and histone methylation are altered rapidly (within days) after treatment with Ara-C. Specifically, H3K27me3 is increased and H3K4me2 is decreased. In order to initially study the contribution of epigenetic changes in primary cells, we have compared the genetic and DNA methylation signature of 140 pairs of AML cells at diagnosis and relapse. Importantly, preliminary evidence suggests that at least 20% of patients have no new detectable genetic abnormalities at relapse. In contrast, when comparing paired diagnosis vs. relapse AML specimens we observe extensive and partially convergent redistribution of cytosine methylation affecting specific pathways, regardless of genetic background. Taken together these studies suggest an epigenetic mechanism of chemotherapy resistance but do not address the role of leukemic stem cells. To address this, we have studied the effect of cytosine arabinoside (Ara-C) on AML cells xenografted in NSG mice. Importantly, we demonstrate for the first time that limiting dilution analysis of Ara-C treatd AML cells does NOT show an enrichment in SCID-leukemia initiating cells. Collectively these data lead us to hypothesize that chemotherapy resistance in AML is a biologically complex event that includes but is not fully explained by genetic lesions and is composed of both fixed and inducible epigenetic elements. To test and explore these ideas, we propose 3 Specific Aims: Specific Aim 1) Identify and characterize candidate mechanisms of epigenetic response to Ara-C in AML cells in vitro. Specific Aim 2) Identify epigenetic and genetic determinants of relapse in primary AML patient samples. Specific Aim 3) Determine the dynamics and mechanism through which chemoresistant features emerge in leukemic cell populations.
 描述(由申请人提供):化疗耐药性是治疗急性髓性白血病(AML)患者最重要的临床挑战。大多数AML患者最初对化疗有反应,但超过一半的反应者会复发并最终死于疾病。传统上,化疗耐药性被假设为代表对具有白血病干细胞(LSC)特性的遗传上不同的克隆的选择。最近 数据和我们的初步结果(如下)表明,该模型的任何一部分都不完全正确。 相反,我们认为化疗耐药性可以并且经常是一种对化疗挑战的后天表观遗传反应,可能出现在任何白血病克隆中。在体外,我们已经模拟了化疗耐药性,并证明了DNA甲基化和组蛋白甲基化在用Ara-C治疗后迅速(在几天内)改变。具体而言,H3 K27 me 3增加,H3 K4 me 2减少。为了初步研究原代细胞中表观遗传变化的贡献,我们比较了140对AML细胞在诊断和复发时的遗传和DNA甲基化特征。重要的是,初步证据表明,至少20%的患者在复发时没有新的可检测的遗传异常。相比之下,当比较配对诊断与复发AML标本时,我们观察到影响特定途径的胞嘧啶甲基化的广泛和部分收敛的再分布, 基因背景。综合这些研究表明化疗耐药的表观遗传机制,但没有解决白血病干细胞的作用。为了解决这个问题,我们研究了阿糖胞苷(Ara-C)对NSG小鼠中异种移植的AML细胞的影响。重要的是,我们第一次证明了阿糖胞苷处理的AML细胞的有限稀释分析没有显示出SCID白血病起始细胞的富集。总的来说,这些数据使我们假设AML中的化疗耐药性是一种生物学复杂事件,包括但不能完全解释遗传病变,并且由固定和诱导的表观遗传因素组成。为了测试和探索这些想法,我们提出了3个具体目标:具体目标1)在体外AML细胞中鉴定和表征对Ara-C的表观遗传反应的候选机制。具体目的2)鉴定原发性AML患者样品中复发的表观遗传和遗传决定因素。3)确定白血病细胞群体中出现化学抗性特征的动力学和机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTIN CARROLL其他文献

MARTIN CARROLL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTIN CARROLL', 18)}}的其他基金

University of Pennsylvania Patient-derived Xenograft Development and Trials Center
宾夕法尼亚大学患者来源的异种移植开发和试验中心
  • 批准号:
    10733231
  • 财政年份:
    2023
  • 资助金额:
    $ 67.94万
  • 项目类别:
University of Pennsylvania Patient-derived Xenograft Development and Trials Center
宾夕法尼亚大学患者来源的异种移植开发和试验中心
  • 批准号:
    10733232
  • 财政年份:
    2023
  • 资助金额:
    $ 67.94万
  • 项目类别:
Acute myeloid leukemia (AML) Research Project
急性髓系白血病(AML)研究项目
  • 批准号:
    10733236
  • 财政年份:
    2023
  • 资助金额:
    $ 67.94万
  • 项目类别:
Pathologic Signaling Pathways in AML Cells
AML 细胞的病理信号通路
  • 批准号:
    10341044
  • 财政年份:
    2021
  • 资助金额:
    $ 67.94万
  • 项目类别:
Pathologic Signaling Pathways in AML Cells
AML 细胞中的病理信号通路
  • 批准号:
    10553601
  • 财政年份:
    2021
  • 资助金额:
    $ 67.94万
  • 项目类别:
Pathologic Signaling Pathways in AML Cells
AML 细胞中的病理信号通路
  • 批准号:
    10010684
  • 财政年份:
    2021
  • 资助金额:
    $ 67.94万
  • 项目类别:
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
了解和针对急性髓系白血病的化疗耐药性
  • 批准号:
    9114538
  • 财政年份:
    2015
  • 资助金额:
    $ 67.94万
  • 项目类别:
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
了解和针对急性髓系白血病的化疗耐药性
  • 批准号:
    9295847
  • 财政年份:
    2015
  • 资助金额:
    $ 67.94万
  • 项目类别:
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
了解和针对急性髓系白血病的化疗耐药性
  • 批准号:
    9512555
  • 财政年份:
    2015
  • 资助金额:
    $ 67.94万
  • 项目类别:
(PDQ5)Integrated Genetic and Epigenetic Prognostication for Acute Myeloid Leukemi
(PDQ5)急性髓性白血病的综合遗传和表观遗传预测
  • 批准号:
    8687082
  • 财政年份:
    2014
  • 资助金额:
    $ 67.94万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 67.94万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了